A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
Active, not recruiting · Phase 3 · NCT02246621
Conditions: Breast Cancer
At a glance
- Research payments reported, 2025
- $168
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 493
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Abemaciclib (drug), Anastrozole (drug), Letrozole (drug), Placebo (drug)
- Dates
- Started 2014-11-06; completion 2026-12
- Results posted
- Yes
The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women with breast cancer. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio.
From ClinicalTrials.gov, last updated 2026-02-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $168 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Oncology Consultants PA $168
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.